Pfizer (PFE)
(Delayed Data from NYSE)
$23.90 USD
-0.07 (-0.29%)
Updated Sep 16, 2025 03:59 PM ET
After-Market: $23.93 +0.03 (0.13%) 5:58 PM ET
3-Hold of 5 3
A Value F Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PFE 23.90 -0.07(-0.29%)
Will PFE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PFE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PFE
MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer
Will GSK Be Able to Resolve Its Vaccine Challenges Anytime Soon?
PFE: What are Zacks experts saying now?
Zacks Private Portfolio Services
CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths
Other News for PFE
Oncology Investment Surge Hits $1.3B as Private Sector Fills Public Funding Gaps
Oncology Investment Surge Hits $1.3B as Private Sector Fills Public Funding Gaps
Moderna Reports 8-Fold Jump In Antibodies With Updated Spikevax
Mixed options sentiment in Pfizer with shares up 0.27%
Mixed options sentiment in Pfizer with shares up 0.27%